Dexcom's first-ever over-the-counter glucose monitor patch gets FDA clearance

Dexcom has received FDA clearance for its first over-the-counter continuous glucose monitor, Stelo, targeting patients with Type 2 diabetes who do not use insulin. This marks the first time a glucose biosensor will be available without a prescription, with sales starting in the summer of 2024. Stelo aims to improve diabetes management by tracking glucose levels in real-time, sending data wirelessly to a smartphone for more effective monitoring of the user's condition.

Opens on CNBC